{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012264","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.802084+00:00","generated_at":"2026-05-15T23:58:21.992497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M","bullets":["Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).","GAAP net income Q4 $2.1M ($0.04 EPS) vs net loss $1.2M; adjusted EBITDA $6.9M (28% of revenue).","2026 guidance: revenue $112.5M-$115.0M (17-20% growth), full-year GAAP net income expected.","Biopreservation media in 16 approved CGT products; >70% share in Phase III CGT trials.","Divested evo in Oct 2025 for $25.5M cash; cash & securities $120.2M at Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012264","json":"https://secwatch.observer/filing/0001628280-26-012264.json","markdown":"https://secwatch.observer/filing/0001628280-26-012264.md","text":"https://secwatch.observer/filing/0001628280-26-012264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/0001628280-26-012264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/blfs-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:58:21.992497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}